Zhang J. · Li H. · Wang S.

Author affiliations

Department of Blood Purification, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: July 19, 2022
Accepted: October 11, 2022
Published online: December 06, 2022

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 1

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

Background: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is not established in chronic kidney disease (CKD) patients. Objective: In this meta-analysis, we evaluated the efficacy and safety of long duration DAPT compared with short duration DAPT in CKD patients after PCI. Methods: We searched PubMed, Cochrane, and Embase to identify studies assessing the effect of DAPT duration in CKD patients with PCI. Endpoints included all-cause mortality, major adverse cardiovascular events (MACE), death or myocardial infarction (MI), revascularization, and bleeding. Event rates were compared with a random-effects model expressed by odds ratio (OR) and 95% confidence interval (CI). Results: Six studies were included. CKD patients with extended DAPT duration were at a lower risk of mortality (OR 1.40, 95% CI: 1.11–1.77), MACE (OR 1.33, 95% CI: 1.17–1.51), mortality or MI (OR 1.24, 95% CI: 1.10–1.40), and stroke (OR 1.28, 95% CI: 1.05–1.56). However, there was no significant difference in revascularization and bleeding events between the two groups. Mortality was higher in patients with dialysis or drug-eluting stent comparing short- to long-term DAPT. Conclusions: Prolonged DAPT might decrease the risk of mortality, MACE, and stroke in patients with CKD without any significant difference in bleeding or revascularization. Additional studies are required to determine whether long-term DAPT could be considered for most CKD patients after PCI.

© 2022 S. Karger AG, Basel

References Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;26(10):2504–11. Engelbertz C, Reinecke H, Breithardt G, Schmieder RE, Fobker M, Fischer D, et al. Two-year outcome and risk factors for mortality in patients with coronary artery disease and renal failure: the prospective, observational CAD-REF Registry. Int J Cardiol. 2017;243:65–72. Gupta T, Paul N, Kolte D, Harikrishnan P, Khera S, Aronow WS, et al. Association of chronic renal insufficiency with in-hospital outcomes after percutaneous coronary intervention. J Am Heart Assoc. 2015;4(6):e002069. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2016;152(5):1243–75. Gargiulo G, Santucci A, Piccolo R, Franzone A, Ariotti S, Baldo A, et al. Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: an analysis from the PRODIGY trial. Catheter Cardiovasc Interv. 2017;90(4):E73–84. Collet JP, Silvain J, Barthélémy O, Rangé G, Cayla G, Van Belle E, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014;384(9954):1577–85. Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014;129(3):304–12. Gilard M, Barragan P, Noryani AAL, Noor HA, Majwal T, Hovasse T, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65(8):777–86. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310(23):2510–22. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;156(6):445–59. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12. Park S, Kim Y, Jo HA, Lee S, Kim MS, Yang BR, et al. Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent implantation in dialysis patients. Clin Kidney J. 2020;13(5):803–12. Chen YT, Chen HT, Hsu CY, Chao PW, Kuo SC, Ou SM, et al. Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis. Clin J Am Soc Nephrol. 2017;12(2):262–71. Asami M, Aoki J, Sato T, Tanimoto S, Watanabe M, Horiuchi Y, et al. Impact of stent type and prolonged dual antiplatelet therapy on long-term clinical outcomes in hemodialysis patients with coronary artery disease. Cardiovasc Interv Ther. 2018;33(1):84–94. Siddiqi OK, Smoot KJ, Dufour AB, Cho K, Young M, Gagnon DR, et al. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Heart. 2015;101(19):1569–76. Kao CC, Wu MS, Chuang MT, Lin YC, Huang CY, Chang WC, et al. Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. PLoS One. 2021;16(8):e0255645. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, et al. Chronic kidney disease and coronary artery disease: JACC State-of-the-art review. J Am Coll Cardiol. 2019;74(14):1823–38. Liu ZH, Yu XQ, Yang JW, Jiang AL, Liu BC, Xing CY, et al. Prevalence and risk factors for vascular calcification in Chinese patients receiving dialysis: baseline results from a prospective cohort study. Curr Med Res Opin. 2018;34(8):1491–500. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–60. Howard TM, Khot UN. Dual antiplatelet therapy after percutaneous coronary intervention: personalize the duration. Cleve Clin J Med. 2021;88(6):325–32. Gargiulo G, Windecker S, da Costa BR, Feres F, Hong MK, Gilard M, et al. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ. 2016;355:i5483. Sharma A, Lavie CJ, Sharma SK, Garg A, Vallakati A, Mukherjee D, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation in patients with and without acute coronary syndrome: a systematic review of randomized controlled trials. Mayo Clin Proc. 2016;91(8):1084–93. Sharma A, Hai O, Garg A, Vallakati A, Lavie CJ, Marmur JD. Duration of dual antiplatelet therapy following drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2017;42(12):404–17. Basaraba JE, Barry AR. Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a meta-analysis. J Cardiol. 2017;69(1):353–8. Li H, Guo W, Dai W, Li L. Short-versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1815–25. Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, et al. Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents: a meta-analysis. Clin J Am Soc Nephrol. 2019;14(6):810–22. Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel ML, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011;57(4):399–408. Baber U, Mehran R, Kirtane AJ, Gurbel PA, Christodoulidis G, Maehara A, et al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the assessment of dual antiplatelet therapy with drug-eluting stents registry. Circ Cardiovasc Interv. 2015;8(6):e001683. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37(4):390–9. Lai CH, Lee WL, Sung SH, Hsu PF, Chen YH, Chan WL, et al. Comparison of bare-metal stent and drug-eluting stent for the treatment of patients undergoing percutaneous coronary intervention for unprotected left main coronary artery disease: long-term result from a single center experience. Acta Cardiol Sin. 2015;31(5):381–9. Chang NC, Hu P, Chen TH, Mao CT, Hung MJ, Yeh CT, et al. Drug-eluting versus bare-metal stents for first myocardial infarction in patients with atrial fibrillation: a nationwide population-based cohort study. PLoS One. 2020;15(1):e0227571. Chen DY, Mao CT, Tsai ML, Hsieh MJ, Lin YS, Cherng WJ, et al. Clinical outcomes of drug-eluting stents vs. Bare-metal stents in acute myocardial infarction patients under dialysis: a nationwide cohort study. Circ J. 2016;80(2):363–70. Su X, Yan B, Wang L, Lv J, Cheng H, Chen Y. Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2019;20(1):309. Chen Y, Tu S, Chen Z, Xia J, Chen B, Chen J, et al. Ticagrelor versus clopidogrel in patients with severe renal insufficiency undergoing PCI for acute coronary syndrome. J Interv Cardiol. 2022;2022:1–9. Palmer SC, Di Micco L, Razavian M, Craig JC, Ravani P, Perkovic V, et al. Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. Am J Kidney Dis. 2013;61(1):112–22. Article / Publication Details

First-Page Preview

Received: July 19, 2022
Accepted: October 11, 2022
Published online: December 06, 2022

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 1

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.